Momordica charantia for type 2 diabetes mellitus.

Included randomized controlled trials comparing momordica charantia with placebo or control intervention, examining 479 participants across four trials with durations of up to three months.

Assessment of the effects of Momordica charantia for type 2 diabetes mellitus through randomized controlled trials.

No statistically significant difference in glycaemic control between momordica charantia and placebo, nor compared to metformin or glibenclamide. Insufficient evidence on efficacy.

High risk of bias in trials, variability in preparations of momordica charantia, and lack of studies on long-term effects or quality of life.